Ultrastructural disposition of adriamycin-associated magnetic albumin microspheres in rats
Pramod K. Gupta
Departments of Pharmacy, University of Otago, Dunedin, New Zealand
Search for more papers by this authorCorresponding Author
Cheung-Tak Hung
Departments of Pharmacy, University of Otago, Dunedin, New Zealand
Departments of Pharmacy, University of Otago, Dunedin, New ZealandSearch for more papers by this authorNarayana S. Rao
Department of Pathology, University of Otago, Dunedin, New Zealand
Search for more papers by this authorPramod K. Gupta
Departments of Pharmacy, University of Otago, Dunedin, New Zealand
Search for more papers by this authorCorresponding Author
Cheung-Tak Hung
Departments of Pharmacy, University of Otago, Dunedin, New Zealand
Departments of Pharmacy, University of Otago, Dunedin, New ZealandSearch for more papers by this authorNarayana S. Rao
Department of Pathology, University of Otago, Dunedin, New Zealand
Search for more papers by this authorAbstract
The ultrastructural disposition of intra-arterially administered adriamycin-associated magnetic albumin microspheres has been investigated. The rat tail was used as the target organ and demarcated into the following three parts: T1, the injection site; T2, the target site; and T3, the posttarget site. Adriamycin HCl (2.0 mg/kg) was administered via the carrier through a cannula fixed at T1. The target site, T2, was exposed to a magnetic field of 8000 G for 30 min postdosing. Animals were sacrificed at scheduled time intervals over a 72-h period, and the tissue samples from T2 were observed by light and transmission electron microscopy. Electron microscopy revealed that microspheres traverse the vascular endothelium of the target tissue as early as 2 h after dosing. Gradual loss of tissue organization and cellular components, as a function of drug exposure time, demonstrated that the pharmacodynamic characteristics of the drug are not altered by its entrapment and delivery via the magnetic microspheres. The study confirms second-order drug targeting in the target tissue of healthy animals.
References and Notes
- 1 Drug Carriers in Biology and Medicine; G. Gregoriadis, Ed.; Academic: London, 1979.
- 2 Drug Delivery Systems; R. L. Juliano, Ed.; Oxford University: London, 1980.
- 3 Targeted Drugs; E. P. Goldberg, Ed.; John Wiley & Sons. New York, 1983.
- 4 Microspheres and Drug Therapy. Pharmaceutical Immunological & Medical Aspects; S. S. Davis; L. Illum; J. G. McVie; E. Tomlinson, Eds.; Elsevier: New York, 1984.
- 5 DeLuca, P. P.; Hickey, A. J.; Hazrati, A. M.; Wedlund, P.; Rypacek, F.; Kanke, M. In Topics in Pharmaceutical Sciences, D. D. Breimer; P. Speiser, Eds.; Elsevier: Amsterdam, 1987; pp 429–442.
- 6 Sato, T.; Kanke, M.; Schroeder, H. G.; DeLuca, P. P. Pharm. Res. 1988, 5, 21–30.
- 7 Gupta, P. K.; Hung, C. T.; Perrier, D. G. Int. J. Pharm. 1986, 33, 137–146.
- 8 Gupta, P. K.; Hung, C. T.; Perrier, D. G. Int. J. Pharm. 1986, 33, 147–153.
- 9 Gupta, P. K.; Hung, C. T.; Perrier, D. G. J. Pharm. Sci. 1987, 76, 141–145.
- 10 Gupta, P. K.; Gallo, J. M.; Hung, C. T.; Perrier, D. G. Drug Devel. Ind. Pharm. 1987, 13, 1471–1482.
- 11 Gupta, P. K.; Hung, C. T.; Lam, F. C.; Perrier, D. G. Int. J. Pharm. 1988, 43, 167–177.
- 12 Gupta, P. K.; Hung, C. T.; Lam, F. C. J. Microencapsulation, In press.
- 13 Tomlinson, E.; Burger, J. J.; Schoonderwoerd, E. M. A.; McVie, J. G.; In Microspheres and Drug Therapy. Pharmaceutical, Immunological & Medical Aspects; S. S. Davis; L. Illum; J. G. McVie; E. Tomlinson, Eds.; Elsevier: NY, 1984; pp 75–90.
- 14 Burger, J. J.; McVie, J. G. Pharm. Wkbl. 1985, 7, 27.
- 15 McArdle, C. S.; Lewi, H.; Willmott, N. 3rd World Conference on Clinical Pharmacology and Experimental Therapeutics, Stockholm, 1986.
- 16 Willmott, N.; Kamel, H. M. H.; Cummings, J.; Stuart, J. F. B.; Florence, A. T. In Microspheres and Drug Therapy. Pharmaceutical, Immunological & Medical Aspects; S. S. Davis; L. Illum; J. G. McVie; E. Tomlinson, Eds.; Elsevier, NY, 1984; pp 205–216.
- 17 Willmott, N.; Cummings, J.; Stuart, J. F. B.; Florence, A. T. Biopharm. Drug Dispos. 1985, 6, 91–104.
- 18 Widder, K. J.; Senyei, A. E.; Ranney, D. F. In Advances in Pharmacology and Chemotherapy; S. Garattini; A. Goldin; F. Howking; I. J. Kopin; R. J. Schnitzer, Eds.; Academic: New York 1979; Vol. 16, pp 213–271.
- 19 Sugibayashi, K.; Okumura, M.; Morimoto, Y. Biomaterials 1982, 3, 181–186.
- 20 Ranney, D. F. Science 1985, 227, 182–184.
- 21 Ranney, D. F. Biochem. Pharmacol. 1986, 35, 1063–1069.
- 22 Gupta, P. K.; Morris, C.; Hung, C. T. Proc. Univ. Otago Med. Sch. 1986, 64, 63–64.
- 23 Ibrahim, A.; Couvreur, P.; Roland, M.; Speiser, P. J. Pharm. Pharmacol. 1983, 35, 59–61.
- 24 Florence, A. T.; Halbert, G. W. Phys. Technol. 1985, 16, 164–176.
- 25 Poznansky, M. J.; Juliano, R. L. Pharmacol. Rev. 1984, 36, 277–336.
- 26 Calabresi, P.; Parks, R. E. In The Pharmacological Basis of Therapeutics, 6th Ed.; A. G. Gilman; L. S. Goodman; A. Gilman, Eds.; McMillan: New York, 1980; pp 1249–1250.
- 27 Poste, G.; Kirsh, R. Biotechnology 1983, 10, 869–878.
- 28 Poste, G. In Receptor-Mediated Targeting of Drugs; G. Gregoriadis; G. Poste; J. Senior; A. Trouet, Eds.; Plenum: New York, 1985; pp 427–474.
- 29 Gallo, J. M.; Hung, C. T.; Perrier, D. G. Int. J. Pharm. 1984, 22, 63–74.
- 30 Gallo, J. M.; Gupta, P. K.; Hung, C. T.; Perrier, D. G. J. Pharm. Sci. 1989, 78, 190–194.
- 31 Lillie, R. D. Histopathologic Technique and Practical Histochemistry, 3rd Ed.; Mc-Graw Hill: New York, 1965.
- 32 Longo, W. E.; Iwato, H.; Lindheimer, T. A.; Goldberg, E. P. J. Pharm. Sci. 1982, 71, 1323–1327.
- 33
Tomlinson, E.;
Burger, J. J.;
Schoonderwoerd, E. M. A.;
Kuik, J.;
Schlotz, F. C.;
McVie, J. G.;
Mills, S.
J. Pharm. Pharmacol.
1982,
34, 88P.
10.1111/j.2042-7158.1982.tb00919.x Google Scholar
- 34 Australian National Drug Service Profile on doxorubicin (1983).
- 35 Broadbent, N. R. G.; Brown, G. E. D.. New Zealand Med. J. 1985, 98, 71.
- 36 Chen, X.; Xue, A.; Morris, V. C.; Ferrans, V. J.; Herman, E. H.; El-Hage, A.; Levander, O. A. J. Nutr. 1986, 116, 2453–2465.
- 37 Rahman, A.; White, G.; More, N.; Schein, P. S. Cancer Res. 1985, 45, 796–803.
- 38 Jaenke, R. S. Cancer Res. 1976, 36, 2958–2966.
- 39 Myers, C. E., McGuire, W. P.; Liss, R. H. Ifrim, L.; Grotzinger, K.; Young, R. C.; Science 1977, 197, 165–176.
- 40 Schmitt-Graff, A.; Scheulen, M. E. Path. Res. Prac. 1986, 181, 168–174.
- 41 Reichenbach, D. D.; Benditt, E. P. Arch. Pathol. 1986, 85, 189–199.
- 42
LeFrak, E. A.;
Pitha, J.;
Rosenhemi, S. A.
Cancer
1973,
32, 302–314.
10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- 43 Henderson, I. C.; Frei, I. E. N. Eng. J. Med. 1979, 300, 310–312.
- 44 Widder, K. J.; Marino, P. A.; Morris, R. M.; Howard, D. P.; Poore, G. A.; Senyei, A. E. Eur. J. Cancer Clin. Oncol. 1983, 19, 141–147.
- 45
Widder, K. J.;
Senyei, A. E.;
Scarpelli, D. G.
Proc. Soc. Exp. Biol. Med.
1978,
58, 141–146.
10.3181/00379727-158-40158 Google Scholar
- 46 Warren, B. A. Microvasc. Res. 1970, 2, 443–453.
- 47 Underwood, J. L. E.; Carr, I. J. Pathol. 1972, 17, 157–166.
- 48
Ward, J. D.;
Hadfield, M. G.;
Becker, D. P.;
Lovings, E. T.;
Cancer
1974,
34, 1982–1991.
10.1002/1097-0142(197412)34:6<1982::AID-CNCR2820340617>3.0.CO;2-G CAS PubMed Web of Science® Google Scholar
- 49 Hirano, A.; Matsui, T. Human Pathol. 1975, 6, 611–621.
- 50 Waggner, J. D.; Beggs, J. L. Adv. Neurol. 1976, 15, 27–49.
- 51 Nugent, L. J.; Jain, R. K. Microvasc. Res. 1984, 28, 270–274.
- 52 Gerlowski, L. E.; Jain, R. K. Microvasc. Res. 1986, 31, 288–305.
- 53 Lazo, J. S. Biochem. Pharmacol. 1986, 35, 1919–1923.
